Neurosearch A/s

Cadent Therapeutics, Inc.

Boehringer Ingelheim International Gmbh

Aniona Aps

Janus Schreiber Larsen

Elsebet Østergaard Nielsen

Lene Teuber

Philip K Ahring

Naheed Mirza

Gregg F Keaney

Martin R Jefson

Thomas Amos Jacobsen

Karin Sandager Nielsen

William Dalby Brown

David Tristram Brown

Dipak Vasantrao Amrutkar

Kelly Foster

John Adams Lowe, Iii

John Michael McCall

Stefan Peters

Birgitte Langer Eriksen

Markus Ostermeier

Charlotte Hougaard

Dorte Strøbæk

Magnus Gustafsson

Yunhai Cui

Oliver Hucke

Florian Binder

Radoslaw Lipinski

Florian Montel

Jessica Klein

Alexandre Perera

Nadia Lybøl Von Schoubye

The present invention relates to difluoromethyl-phenyl triazoles of general formula (I) which are modulators of GABAreceptors containing the &#x3b1;5 subunit, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

Difluoromethyl-phenyl triazoles

Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels. 

Potassium channel modulators

Provided are compounds of the formula: and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with potassium channels.

Provided herein are compounds of the formula: or pharmaceutically acceptable salts thereof, and compositions comprising such compounds for use in the treatment of diseases or conditions responsive to modulation of the small conductance calcium-activated potassium channel (SK channel).

The present application discloses novel benzimidazole derivatives and their use as modulators of the GABAreceptor complex. In other aspects the application discloses the use of these compounds, in a method for therapy and to pharmaceutical compositions comprising these compounds.

[object Object]

Benzimidazole derivatives, pharmaceutical compositions containing them, and methods of treatment therewith involving modulation of the GABAreceptor complex. The compounds have the formula I: wherein the variables are as described in the specification. The compounds are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

Imidazole derivatives for the treatment of anxiety and related diseases

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases.

This invention relates to novel imidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are of the general formula (I) and include any of its stereoisomers, any mixture of its stereoisomers, and pharmaceutically acceptable salts thereof. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases. 

This invention relates to novel benzimidazole derivatives of formula (I), pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAreceptor complex, and in particular for combating anxiety and related diseases 

Growing community of inventors

Holbæk, Denmark

Janus Schreiber Larsen